Sartorius Stedim Biotech — AGM Information 2017

Apr 4, 2017

Resolutions of the Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A.

Aubagne, April 4, 2017 – At today's Annual General Shareholders' Meeting (AGM) of Sartorius Stedim Biotech S.A. in Aubagne, France, shareholders approved the Board of Directors' proposals by a large majority.

The AGM thus passed the resolution to pay a dividend of €0.42 net per share for fiscal 2016. The previous year's dividend, adjusted for the stock split that was implemented in June 2016, was €0.33. The total profit distributed will therefore rise by 26.0% from €30.7 million to €38.7 million.

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. In 2016, the company employed approx. 4,700 people, and earned sales revenue of 1,051.6 million euros.

Contact

Petra Kirchhoff; Vice President of Corporate Communications Phone: +49(0)551.308.1686 ; petra.kirchhoff@sartorius.com